Eyeing potential 15th local biotech IPO, EyeGate plans $25M stock sale

Following a week in which neither of two expected local biotech IPOs were carried out, a Waltham biotech with a new approach for getting drugs to the back of the eye is planning a modest $25 million stock offering for next week...